BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alliance Pharma plc Release: Preliminary Results for the Year Ended 31 December 2007


3/18/2008 4:22:49 PM

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to announce its preliminary results for the year ended 31 December 2007.

Financial Highlights

• Sales up 6% to £18.2m (2006: £17.3m) • Operating profit* up 39% to £3.6m (2006: £2.6m) • Step change in profitability mid-year, with £1.1m pre-tax profit* in the second half of 2007 • Full year pre-tax profit* of £0.4m (2006: £0.5m) • Cash flow from operations of £4.1m (2006: £1.1m) • Non-cash impairment charge of £3.4m in respect of Posidorm® *Before exceptional items

Operational Highlights

• Acquisition of Forceval® rights in China through new joint venture • Successful completion of Phase III trial for Isprelor®, with encouraging reaction from potential prescribers • Strategy implemented to increase profitability and cash generation • Mid-year reorganisation reduced overheads by more than £1m annually Commenting on the results, Michael Gatenby, Alliance’s Chairman, said: “We are greatly encouraged by the speed and effectiveness of the turnaround in the second half of 2007. Following the decisive action we took, Alliance has delivered the best six months’ performance in its history. The current year has begun well. Provided there is no unexpected setback on pricing, we are confident that the improved profitability achieved in the second half of 2007 will be sustainable through 2008.”

For further information:

Alliance Pharma plc + 44 (0) 1249 466966 John Dawson, Chief Executive Richard Wright, Finance Director www.alliancepharma.co.uk

Buchanan Communications + 44 (0) 20 7466 5000 Mark Court / Rebecca Skye Dietrich / Catherine Breen

Numis Securities + 44 (0) 20 7260 1000 David Poutney / Michael Meade / Nick Westlake



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES